Showing results (161-170 of 193) with videos related to
Sort By:
Pageof 20
International Journal of Cancer|October 31, 2009
Androgen-regulated gastrin-releasing peptide receptor expression in androgen-dependent human prostate tumor xenograftsRogier P J Schroeder, Monique de Visser, Wytske M van Weerden, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 16, 2008
Reducing renal uptake of radiolabeled peptides using albumin fragmentsErik Vegt, Julliëtte E M van Eerd, Annemarie Eek, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2006
213Bi-[DOTA0, Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal modelJeffrey P Norenberg, Boudewijn J Krenning, Inge R H M Konings, et al.International Journal of Molecular Sciences|July 27, 2022
Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer TreatmentEline A M Ruigrok, Nicole S Verkaik, Erik de Blois, et al.European Journal of Nuclear Medicine and Molecular Imaging|February 26, 2010
A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analoguesRogier P J Schroeder, Cristina Müller, Suzanne Reneman, et al.EJNMMI Research|March 17, 2021
Autoradiographical assessment of inflammation-targeting radioligands for atherosclerosis imaging: potential for plaque phenotype identificationEric J Meester, Erik de Blois, Boudewijn J Krenning, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 18, 2005
Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotateRoelf Valkema, Stanislas A Pauwels, Larry K Kvols, et al.Cancer Biotherapy & Radiopharmaceuticals|May 14, 2014
[(111)In-DTPA]octreotide tumor uptake in GEPNET liver metastases after intra-arterial administration: an overview of preclinical and clinical observations and implications for tumor radiation dose after peptide radionuclide therapyStefan E Pool, Boen L R Kam, Gerben A Koning, et al.Cancer Biotherapy & Radiopharmaceuticals|July 27, 2007
Five Stabilized 111In-labeled neurotensin analogs in nude mice bearing HT29 tumorsPaul J J M Janssen, Moniaue de Visser, Suzanne M Verwijnen, et al.Molecular Imaging and Biology|June 10, 2020
In Vivo Evaluation of Indium-111-Labeled 800CW as a Necrosis-Avid Contrast AgentMarcus C M Stroet, Erik de Blois, Debra C Stuurman, et al.Pageof 20